Filing Overview
Phathom Pharmaceuticals, Inc. filed a Form 8-K dated April 29, 2021, under Item 8.01 (Other Events). The filing reports interim results from the pivotal Phase 3 PHALCON-HP trial evaluating vonoprazan-based regimens for eradication of Helicobacter pylori infection.
Clinical and Operating Highlights
- PHALCON-HP randomized 992 patients and compared vonoprazan triple therapy, vonoprazan dual therapy, and lansoprazole triple therapy.
- In the modified intent-to-treat population, eradication rates were 84.7% for vonoprazan triple therapy, 78.5% for vonoprazan dual therapy, and 78.8% for lansoprazole triple therapy. Both vonoprazan regimens met their non-inferiority primary endpoints.
- In the per-protocol population, eradication rates were 90.4%, 81.2%, and 82.1%, respectively; both vonoprazan regimens again met non-inferiority endpoints.
- Vonoprazan triple and dual therapy achieved statistically superior eradication rates versus lansoprazole triple therapy in all-patient analyses and in patients with clarithromycin-resistant strains.
- Clarithromycin-resistant strains represented 20.3% of the study population. In the mITT population, eradication rates for resistant strains were 65.8% for vonoprazan triple therapy, 69.6% for vonoprazan dual therapy, and 31.9% for lansoprazole triple therapy.
- Both vonoprazan regimens were generally well tolerated, with safety profiles comparable to the control regimen. Discontinuation due to adverse events was 2.3% for triple therapy, 0.9% for dual therapy, and 1.4% for lansoprazole triple therapy.
Financial Metrics and Liquidity
This Item 8.01 filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial statement metrics. The filing text does not provide a clear value for these items.
Material Changes and Outlook
- In April 2021, the company commenced enrollment in a Phase 2 trial evaluating on-demand vonoprazan dosing for non-erosive reflux disease.
- Phathom plans to submit FDA new drug applications for vonoprazan triple therapy and dual therapy for H. pylori infection in the fourth quarter of 2021.
- The company expects to report top-line data from the ongoing pivotal Phase 3 PHALCON-EE trial in erosive gastroesophageal reflux disease in the fourth quarter of 2021.
- Full PHALCON-HP results are expected to be presented at a future medical meeting and submitted for publication in a peer-reviewed journal.
Risks, Contingencies, and Unusual Items
- The reported results are based on preliminary analyses and remain subject to audit and verification, which could result in material changes to final data.
- FDA feedback could differ from prior discussions and could delay or affect NDA submissions, regulatory review, or approval.
- Vonoprazan remains subject to risks involving safety, efficacy, manufacturing, clinical testing, regulatory developments, intellectual property, licensing obligations with Takeda, and commercialization.
- Pending qualified infectious disease product requests may not be granted, and existing QIDP or Fast Track designations do not assure FDA approval.
- COVID-19 could disrupt clinical trials, manufacturing, supply chains, and other business operations.
Key Facts for Investors to Verify
- Final, audited PHALCON-HP efficacy and safety results, including whether they differ from the preliminary top-line analysis.
- FDA acceptance, filing, and review status of the planned NDAs.
- Timing and results of the PHALCON-EE trial.
- Financial condition, cash runway, funding requirements, debt, and operating expenses, which are not addressed in this filing.
- Regulatory designations, intellectual property protection, Takeda license compliance, manufacturing readiness, and potential COVID-19-related disruptions.